SIHUAN PHARM (00460) has announced that the Group has officially entered into a strategic collaboration agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 688796.SH; 02315.HK). Based on principles of complementary strengths and professional synergy, the partnership will leverage the Group's extensive experience across the entire pharmaceutical industry chain, including drug development, large-scale production, and commercialization. This will be combined with Biocytogen's industry-leading, AI-driven platform for developing fully human antibodies. The collaboration aims to jointly research and develop innovative drugs in several high-potential disease areas, including weight loss, establishing a long-term, stable, and mutually beneficial relationship to advance the development and commercialization of cutting-edge global innovative medicines.

The first project under this strategic collaboration will focus on the Group's investigational next-generation innovative drug for weight reduction. This R&D project is designed to achieve technological breakthroughs addressing current industry challenges in weight loss therapies. Through a novel mechanism of action, it aims to enable safe and efficient increases in energy expenditure while simultaneously maintaining and enhancing muscle mass. This approach precisely meets significant unmet clinical needs in the global obesity treatment market and has the potential to drive the optimization and upgrading of weight loss treatment regimens, thereby contributing to industry progress.

The pharmaceutical R&D sector is currently undergoing a profound transformation towards greater integration of artificial intelligence and efficiency. The deep integration of AI and automation technologies with antibody drug development has become an inevitable industry trend. The "AI + high-throughput" R&D model is leading an efficiency revolution within the sector, effectively shortening antibody drug development cycles, reducing R&D costs, and accelerating the design and screening of global first-in-class drugs, thereby helping innovative drug companies build core competitive advantages.

The Group highly recognizes Biocytogen's technical capabilities and industry standing in AI-driven antibody research, gene editing, and model animal fields. For this collaboration, Biocytogen will fully utilize its comprehensive technological advantages, including its self-developed model animal and pharmacodynamic evaluation platforms, fully human antibody discovery platform, and AI-powered antibody drug R&D platform. This will provide all-around, high-standard technical support for the joint projects, ensuring their efficient advancement.